DE602006018578D1 - Diagnose- und prognoseverfahren von blasenkrebs. - Google Patents

Diagnose- und prognoseverfahren von blasenkrebs.

Info

Publication number
DE602006018578D1
DE602006018578D1 DE602006018578T DE602006018578T DE602006018578D1 DE 602006018578 D1 DE602006018578 D1 DE 602006018578D1 DE 602006018578 T DE602006018578 T DE 602006018578T DE 602006018578 T DE602006018578 T DE 602006018578T DE 602006018578 D1 DE602006018578 D1 DE 602006018578D1
Authority
DE
Germany
Prior art keywords
cancer
diagnosis
prognosis
bubble
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006018578T
Other languages
English (en)
Inventor
Bruce R Zetter
Adam S Feldman
Scott W Mcdougal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Childrens Medical Center Corp
Original Assignee
General Hospital Corp
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Childrens Medical Center Corp filed Critical General Hospital Corp
Publication of DE602006018578D1 publication Critical patent/DE602006018578D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
DE602006018578T 2005-01-28 2006-01-30 Diagnose- und prognoseverfahren von blasenkrebs. Active DE602006018578D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64811005P 2005-01-28 2005-01-28
PCT/US2006/003049 WO2006081473A2 (en) 2005-01-28 2006-01-30 Methods for diagnosis and prognosis of epithelial cancers

Publications (1)

Publication Number Publication Date
DE602006018578D1 true DE602006018578D1 (de) 2011-01-13

Family

ID=36741098

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018578T Active DE602006018578D1 (de) 2005-01-28 2006-01-30 Diagnose- und prognoseverfahren von blasenkrebs.

Country Status (9)

Country Link
US (7) US8685659B2 (de)
EP (1) EP1842065B1 (de)
JP (1) JP2008529008A (de)
CN (1) CN101268368A (de)
AT (1) ATE490465T1 (de)
AU (1) AU2006207954A1 (de)
CA (1) CA2595377A1 (de)
DE (1) DE602006018578D1 (de)
WO (1) WO2006081473A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
EP1512970A1 (de) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verfahren zur Bestimmung der Wirkung einer Zusammensetzung auf das Profil einer Krankheit
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CN101268368A (zh) * 2005-01-28 2008-09-17 儿童医疗中心有限公司 上皮癌的诊断和预后方法
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
EP2530168B1 (de) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
KR100767878B1 (ko) * 2006-11-07 2007-10-17 전북대학교산학협력단 간세포암 진단용 조성물, 이를 포함하는 간세포암 진단키트 및 간세포암 진단방법
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
JP2010519529A (ja) * 2007-02-23 2010-06-03 プレディクティブ バイオサイエンシーズ コーポレイション 臨床的介入を指向する診断方法
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2009017475A1 (en) * 2007-07-27 2009-02-05 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
JP5120843B2 (ja) * 2008-06-04 2013-01-16 国立大学法人山梨大学 自己免疫性膵炎の検査方法及び検査試薬
EP4047367A1 (de) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
EP2411148B1 (de) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation von mikrofluidiktröpfchen
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP3392349A1 (de) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Digitale analyse von analyten
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
CA3067107C (en) 2010-06-03 2022-07-12 Idexx Laboratories, Inc. Markers for renal disease
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3412778A1 (de) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
EP3736281A1 (de) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2714970B1 (de) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Enzymquantifizierung
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US20130115599A1 (en) * 2011-11-08 2013-05-09 Medical Diagnostic Laboratories, Llc Increased cip2a expression and bladder cancer in humans
US20130210659A1 (en) 2012-02-10 2013-08-15 Andrew Watson Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
AU2013359398B2 (en) * 2012-12-11 2019-08-15 Cornell University Methods for diagnosing and treating prostate cancer
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
EP3090063B1 (de) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Verfahren zur detektion von latentem retrovirus
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
AR107786A1 (es) * 2016-03-02 2018-06-06 Idexx Lab Inc Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US20230314408A1 (en) * 2020-07-02 2023-10-05 Gopath Laboratories Llc Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer
CN112379093B (zh) * 2020-10-22 2023-06-16 上海良润生物医药科技有限公司 CST-Cathepsin复合物作为肿瘤诊断标志物的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5118937A (en) 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
AU3602097A (en) 1996-07-15 1998-02-09 Regents Of The University Of California, The Genes from 20q13 amplicon and their uses
JPH10262680A (ja) * 1997-03-25 1998-10-06 Kirin Brewery Co Ltd Ｒｈｏ標的タンパク質ヒトｍＤｉａおよびその遺伝子
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6642007B1 (en) * 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
US20030124543A1 (en) 1999-01-15 2003-07-03 Stuart Susan G. Breast cancer marker
US6358683B1 (en) 1999-06-03 2002-03-19 The Regents Of The University Of California Blood-based assays for breast cancer
US6939714B2 (en) * 1999-06-18 2005-09-06 Biotherapies, Inc. Epithelial cell growth inhibitors
WO2001018058A2 (en) 1999-09-07 2001-03-15 Viventia Biotech Inc. Enhanced phage display library of human vh fragments and methods for producing same
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US20040142361A1 (en) * 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US20030077616A1 (en) 2001-04-19 2003-04-24 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
IL160324A0 (en) 2001-08-13 2004-07-25 Beyond Genomics Inc Method and system for profiling biological systems
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
US20030157579A1 (en) * 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
AU2003239152A1 (en) 2002-04-23 2003-11-10 Millipore Corporation Sample preparation of biological fluids for proteomic applications
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
EP2060918A3 (de) * 2003-04-01 2009-08-26 The Johns Hopkins University Endothelzellen-Expressionsmuster in der Brust
CN101268368A (zh) * 2005-01-28 2008-09-17 儿童医疗中心有限公司 上皮癌的诊断和预后方法
WO2009017475A1 (en) 2007-07-27 2009-02-05 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers

Also Published As

Publication number Publication date
US20090239245A1 (en) 2009-09-24
CA2595377A1 (en) 2006-08-03
WO2006081473A2 (en) 2006-08-03
WO2006081473A3 (en) 2007-01-18
US20150093767A1 (en) 2015-04-02
CN101268368A (zh) 2008-09-17
EP1842065B1 (de) 2010-12-01
WO2006081473A8 (en) 2007-08-23
AU2006207954A1 (en) 2006-08-03
EP1842065A4 (de) 2008-12-31
JP2008529008A (ja) 2008-07-31
US20180188252A1 (en) 2018-07-05
US20180120319A1 (en) 2018-05-03
ATE490465T1 (de) 2010-12-15
EP1842065A2 (de) 2007-10-10
US20170023574A1 (en) 2017-01-26
US20140106378A1 (en) 2014-04-17
US20080064047A1 (en) 2008-03-13
US8685659B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ATE476657T1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
ATE524740T1 (de) Seprase als krebsmarker
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
ATE554386T1 (de) Verbesserte immunoassayverfahren
GB2467704A (en) Methods of monitoring conditions by sequence analysis
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2007008759A3 (en) Methods for detecting and confirming minimal disease in a cancer patient
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
BR0314155A (pt) Métodos para diagnosticar câncer cervical
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
DE602006018458D1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
WO2007060240A3 (fr) Procede pour la mise en evidence de la presence ou de l ' absence de marquers (eef1a1 ou mark3 ) associes a la presence et/ou a la chimiosensibilite des tumeurs